Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: To describe the phenotype of patients with C9FTD/ALS (C9ORF72) hexanucleotide repeat expansion.
Methods: A total of 648 patients with frontotemporal dementia (FTD)-related clinical diagnoses and Alzheimer disease (AD) dementia were tested for C9ORF72 expansion and 31 carried expanded repeats (C9+). Clinical and neuroimaging data were compared between C9+ (15 behavioral variant FTD [bvFTD], 11 FTD-motor neuron disease [MND], 5 amyotrophic lateral sclerosis [ALS]) and sporadic noncarriers (48 bvFTD, 19 FTD-MND, 6 ALS).
Results: All C9+ patients displayed clinical syndromes of bvFTD, ALS, or FTD-MND. At first evaluation, C9+ bvFTD patients had more delusions and greater impairment of working memory, but milder eating dysregulation compared to bvFTD noncarriers. C9+FTD-MND patients had a trend for longer survival and had an earlier age at onset than FTD-MND noncarriers. Voxel-based morphometry demonstrated more thalamic atrophy in FTD and FTD-MND carriers than in noncarriers.
Conclusions: Patients with the C9ORF72 hexanucleotide repeat expansion develop bvFTD, ALS, or FTD-MND with similar clinical and imaging features to sporadic cases. Other FTD spectrum diagnoses and AD dementia appear rare or absent among C9+ individuals. Longer survival in C9+ FTD-MND suggests slower disease progression and thalamic atrophy represents a novel and unexpected feature.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3430713 | PMC |
| http://dx.doi.org/10.1212/WNL.0b013e318268452e | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Machine-Learning Applications in Frontotemporal Dementia: Challenges, Prospects and Viable Clinical Applications.
Eur J Neurol
September 2025
Department of Neurology, University of Ulm, Ulm, Germany.
Low Frequency of Dementia with Lewy Bodies Diagnosis in a Colombian Memory Clinic.
Mov Disord Clin Pract
September 2025
Centre for Age-Related Medicine (SESAM), Stavanger University Hospital, Stavanger, Norway.
Background: The global burden of dementia is increasing, particularly in low- and middle-income countries. Dementia with Lewy bodies (DLB) is the second most common neurodegenerative dementia but remains underreported and frequently misdiagnosed. Its prevalence in Latin America is largely unknown.
View Article and Find Full Text PDFEmerging Molecular Targets in Neurodegenerative Disorders: New Avenues for Therapeutic Intervention.
Basic Clin Pharmacol Toxicol
October 2025
Department of Medical Pharmacology, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey.
Neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis and frontotemporal dementia represent a significant global health burden with limited therapeutic options. Current treatments are primarily symptomatic and fail to modify disease progression, emphasizing the urgent need for novel, mechanism-based interventions. Recent advances in molecular neuroscience have identified several non-classical pathogenic pathways, including neuroinflammation, mitochondrial dysfunction, impaired autophagy and proteostasis, synaptic degeneration and non-coding RNA dysregulation.
View Article and Find Full Text PDFPlasma lipidome dysregulation in frontotemporal dementia reveals shared, genotype-specific, and severity-linked alterations.
Alzheimers Dement
September 2025
Cell Biology Program, Sloan Kettering Institute, New York, New York, USA.
Introduction: Biomarkers are essential for monitoring the progression of frontotemporal dementia (FTD). Although dysregulated brain lipid metabolism, particularly sphingolipids enriched in the nervous system, is a key feature of neurodegeneration, plasma lipids remain underexplored as biomarkers compared to imaging and serum proteins.
Methods: We examined plasma lipidomes using liquid chromatography-tandem mass spectrometry (LC-MS/MS) from individuals carrying pathogenic variants linked to autosomal dominant FTD (GRN, C9orf72, MAPT) and non-carriers.
Reduced harm aversion relates to antisocial behaviors and orbitofrontal atrophy in dementia patients.
Alzheimers Dement
September 2025
Department of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Introduction: Antisocial behaviors occur in dementia, but the underlying neurocognitive mechanisms remain underexplored. We administered a decision-making task measuring patients' harm aversion by offering options to shock themselves or another person in exchange for money, hypothesizing that task performance would relate to antisocial behaviors and ventromedial/orbitofrontal cortex (vmPFC/OFC) atrophy.
Methods: Among 43 dementia patients (n = 23 behavioral variant frontotemporal dementia [bvFTD], n = 20 Alzheimer's disease [AD]), we used linear regressions to measure relationships between harm aversion and antisocial behavior, psychopathic personality traits, socioemotional functions, and vmPFC/OFC cortical thickness, controlling for age, sex, and cognitive dysfunction.